Phaseline

Companies › Zealand Pharma

Zealand Pharma: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 3; Immunology, Other, Gastroenterology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Glepaglutide–Phase 3Short Bowel Syndrome (SBS); Short Bowel SyndromeSep 2028
ZP9830–Phase 1Healthy Volunteers; Plaque PsoriasisApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06682975ZP9830Phase 1Healthy VolunteersOtherAug 2026
NCT07733089ZP9830Phase 1Plaque PsoriasisImmunologyApr 2027
NCT07228403GlepaglutidePhase 3Short Bowel Syndrome (SBS)GastroenterologySep 2028
NCT07197944GlepaglutidePhase 3Short Bowel SyndromeGastroenterologyOct 2028

From the company's SEC filings

Complete response letters from FDA

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Forte Biosciences Novadip Biosciences Astria Therapeutics Pacira Pharmaceuticals Onconic Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.